Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.6283
-0.0108 (-1.69%)
At close: Aug 29, 2025, 4:00 PM
0.6247
-0.0036 (-0.57%)
After-hours: Aug 29, 2025, 6:39 PM EDT
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $72.10K. In the year 2024, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
42.65
Revenue / Employee
$24,034
Employees
3
Market Cap
5.94M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 72.10K | - | - |
Dec 31, 2023 | 72.10K | - | - |
Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
Dec 31, 2021 | 71.26K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SILO News
- 11 days ago - Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - GlobeNewsWire
- 13 days ago - Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway - GlobeNewsWire
- 27 days ago - Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform - GlobeNewsWire
- 6 weeks ago - Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 - GlobeNewsWire
- 2 months ago - Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 - GlobeNewsWire
- 2 months ago - Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market - GlobeNewsWire
- 2 months ago - Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. - PRNewsWire
- 2 months ago - Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - GlobeNewsWire